TR201905586T4 - Amorf dapagli̇flozi̇n i̇çeren formülasyonlar - Google Patents
Amorf dapagli̇flozi̇n i̇çeren formülasyonlar Download PDFInfo
- Publication number
- TR201905586T4 TR201905586T4 TR2019/05586T TR201905586T TR201905586T4 TR 201905586 T4 TR201905586 T4 TR 201905586T4 TR 2019/05586 T TR2019/05586 T TR 2019/05586T TR 201905586 T TR201905586 T TR 201905586T TR 201905586 T4 TR201905586 T4 TR 201905586T4
- Authority
- TR
- Turkey
- Prior art keywords
- dapagliflozine
- amorf
- formulations containing
- present
- pharmaceutical compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 239000002156 adsorbate Substances 0.000 abstract 1
- 229960003834 dapagliflozin Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mechanical Engineering (AREA)
- Composite Materials (AREA)
Abstract
Mevcut buluş farmasötik endüstrisi alanına ait olup özellikle de katı dispersiyonlar ve adsorbatlar şeklinde amorf dapagliflozin içeren farmasötik kompozisyonlar ve bunların hazırlanması için bir prosesle ilgilidir. Buna ilaveten, söz konusu buluş hipoglisemi ile ilgili hastalıkların tedavisinde kullanmak üzere sözü edilen farmasötik kompozisyonların kullanımıyla da ilgilidir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13177508 | 2013-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201905586T4 true TR201905586T4 (tr) | 2019-05-21 |
Family
ID=48874149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/05586T TR201905586T4 (tr) | 2013-07-22 | 2014-07-22 | Amorf dapagli̇flozi̇n i̇çeren formülasyonlar |
Country Status (12)
Country | Link |
---|---|
US (2) | US20160256433A1 (tr) |
EP (1) | EP3024442B1 (tr) |
JP (2) | JP6574417B2 (tr) |
KR (1) | KR20160034348A (tr) |
CN (2) | CN105555258A (tr) |
AU (2) | AU2014295137B2 (tr) |
CA (1) | CA2918570A1 (tr) |
ES (1) | ES2721059T3 (tr) |
MX (1) | MX370853B (tr) |
PT (1) | PT3024442T (tr) |
TR (1) | TR201905586T4 (tr) |
WO (1) | WO2015011113A1 (tr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3110402A1 (en) * | 2014-02-28 | 2017-01-04 | Sun Pharmaceutical Industries Ltd | Dapagliflozin compositions |
WO2016161995A1 (en) * | 2015-04-08 | 2016-10-13 | Zentiva, K.S. | Solid forms of amorphous dapagliflozin |
US10556877B2 (en) * | 2015-05-05 | 2020-02-11 | Glenmark Life Sciences Limited | Process for preparation of dapagliflozin |
CZ2015435A3 (cs) * | 2015-06-25 | 2017-01-04 | Zentiva, K.S. | Pevné formy amorfního canagliflozinu |
WO2017042683A1 (en) * | 2015-09-07 | 2017-03-16 | Dr. Reddy's Laboratories Limited | Isolated intermediate of dapagliflozin, process for the preparation of isolated intermediate of dapagliflozin, process for the preparation of dapagliflozin |
US9845303B2 (en) | 2015-10-19 | 2017-12-19 | Cadila Healthcare Limited | Process for the preparation of dapagliflozin |
CN106727368A (zh) * | 2015-11-24 | 2017-05-31 | 上海星泰医药科技有限公司 | 一种达格列净药物组合物及其制备方法 |
EP3380079A4 (en) * | 2015-11-25 | 2019-08-21 | Patheon Development Services Inc. | AMORPHOUS DISPERSION GRANULES AND PHARMACEUTICAL FORMS FOR ORAL USE |
ITUB20156299A1 (it) * | 2015-12-03 | 2017-06-03 | S B M S R L | Prodotto comprendente collagene e almeno un farmaco amorfo micronizzato, procedimento per la sua preparazione e relativi usi in campo medico. |
WO2017118945A1 (en) | 2016-01-08 | 2017-07-13 | Lupin Limited | Premix of dapagliflozin and process for the preparation thereof |
JP7082067B2 (ja) | 2016-05-13 | 2022-06-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 溶融押出用途のためのポリマーの粒子サイズおよび分布 |
WO2017203229A1 (en) | 2016-05-27 | 2017-11-30 | Cipla Limited | Dapagliflozin premixes |
KR20180058510A (ko) * | 2016-11-24 | 2018-06-01 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 약제학적 제제 |
WO2018167589A1 (en) * | 2017-03-16 | 2018-09-20 | Inventia Healthcare Private Limited | Pharmaceutical composition comprising dapagliflozin |
KR102025480B1 (ko) | 2017-12-12 | 2019-09-25 | 영남대학교 산학협력단 | 다파글리플로진 유리염기를 함유하는 약제학적 조성물 및 이의 제조방법 |
KR102204439B1 (ko) | 2018-05-14 | 2021-01-18 | 에이치케이이노엔 주식회사 | Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물 |
JP7370126B2 (ja) * | 2018-11-27 | 2023-10-27 | 日本化薬株式会社 | エルロチニブを有効成分とする医薬錠剤 |
CN110279666B (zh) * | 2019-05-20 | 2022-05-13 | 湖北万润医药有限公司 | 一种盐酸曲美他嗪片及其制备方法 |
KR102234154B1 (ko) * | 2019-06-18 | 2021-03-31 | 삼천당제약주식회사 | 다파글리플로진비용매화물 함유 정제 제조방법 및 그에 의해 제조된 다파글리플로진비용매화물 함유 정제 |
KR20220054311A (ko) | 2019-08-28 | 2022-05-02 | 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 | 선형 폴리(아크릴산) 중합체를 사용한 약물-중합체 무정형 고체 분산체 |
EP4106732A1 (en) | 2020-02-21 | 2022-12-28 | Zaklady Farmaceutyczne Polpharma S.A. | Pharmaceutical composition comprising dapagliflozin |
WO2021176096A1 (en) | 2020-03-05 | 2021-09-10 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising sglt2 inhibitor |
WO2021245253A1 (en) | 2020-06-05 | 2021-12-09 | Krka, D.D., Novo Mesto | Preparation of highly pure amorphous dapagliflozin |
TR202019592A2 (tr) * | 2020-12-03 | 2022-06-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Amorf dapagliflozinin katı farmasötik formülasyonları |
CN115869265A (zh) * | 2023-01-04 | 2023-03-31 | 聊城高新生物技术有限公司 | 一种达格列净固体分散体和一种药物制剂及其制备方法 |
CN116421595B (zh) * | 2023-02-21 | 2024-03-29 | 深圳市新阳唯康科技有限公司 | 一种达格列净药物组合物及制备方法和应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60028754T2 (de) * | 1999-11-12 | 2007-05-31 | Abbott Laboratories, Abbott Park | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin |
CA2426263C (en) * | 2000-10-24 | 2010-05-25 | Ajinomoto Co., Inc. | Nateglinide-containing preparation |
BR0317929A (pt) * | 2003-01-03 | 2006-04-11 | Bristol Myers Squibb Co | métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila |
WO2008064259A2 (en) * | 2006-11-21 | 2008-05-29 | Biokey, Inc. | Solid dispersion composition comprising fluvastatin |
TW200904405A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
CN102015284A (zh) * | 2008-02-28 | 2011-04-13 | 温帕克热密封包装公司 | 用于压出式泡罩包装的挤出包覆的罩箔 |
WO2010045656A2 (en) * | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
MX2012005365A (es) * | 2009-11-13 | 2012-05-29 | Bristol Myers Squibb Co | Formulaciones de tableta de liberacion inmediata. |
EP2389927A1 (en) * | 2010-05-30 | 2011-11-30 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of rasagiline |
KR20130126451A (ko) * | 2010-05-31 | 2013-11-20 | 아스테라스 세이야쿠 가부시키가이샤 | 트라이아졸 화합물의 고체 분산체 |
MX2013002146A (es) * | 2010-09-03 | 2013-04-03 | Astrazeneca Uk Ltd | Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua. |
WO2012163546A1 (en) * | 2011-06-03 | 2012-12-06 | Ratiopharm Gmbh | Pharmaceutical composition comprising dapagliflozin and cyclodextrin |
-
2014
- 2014-07-22 PT PT14741876T patent/PT3024442T/pt unknown
- 2014-07-22 MX MX2016001023A patent/MX370853B/es active IP Right Grant
- 2014-07-22 KR KR1020167004032A patent/KR20160034348A/ko not_active Application Discontinuation
- 2014-07-22 EP EP14741876.8A patent/EP3024442B1/en active Active
- 2014-07-22 TR TR2019/05586T patent/TR201905586T4/tr unknown
- 2014-07-22 AU AU2014295137A patent/AU2014295137B2/en active Active
- 2014-07-22 ES ES14741876T patent/ES2721059T3/es active Active
- 2014-07-22 CN CN201480051021.4A patent/CN105555258A/zh active Pending
- 2014-07-22 US US14/905,990 patent/US20160256433A1/en not_active Abandoned
- 2014-07-22 CN CN201810833742.0A patent/CN108938583B/zh active Active
- 2014-07-22 CA CA2918570A patent/CA2918570A1/en not_active Abandoned
- 2014-07-22 JP JP2016528493A patent/JP6574417B2/ja active Active
- 2014-07-22 WO PCT/EP2014/065661 patent/WO2015011113A1/en active Application Filing
-
2018
- 2018-06-20 JP JP2018116961A patent/JP2018184410A/ja active Pending
-
2019
- 2019-01-03 AU AU2019200016A patent/AU2019200016A1/en not_active Abandoned
- 2019-01-24 US US16/256,490 patent/US20190175543A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2015011113A1 (en) | 2015-01-29 |
AU2014295137B2 (en) | 2019-01-17 |
KR20160034348A (ko) | 2016-03-29 |
PT3024442T (pt) | 2019-05-16 |
CA2918570A1 (en) | 2015-01-29 |
JP6574417B2 (ja) | 2019-09-11 |
CN108938583A (zh) | 2018-12-07 |
CN105555258A (zh) | 2016-05-04 |
JP2018184410A (ja) | 2018-11-22 |
EP3024442A1 (en) | 2016-06-01 |
US20160256433A1 (en) | 2016-09-08 |
AU2019200016A1 (en) | 2019-01-24 |
AU2014295137A1 (en) | 2016-03-10 |
EP3024442B1 (en) | 2019-01-16 |
MX370853B (es) | 2020-01-08 |
JP2016525527A (ja) | 2016-08-25 |
ES2721059T3 (es) | 2019-07-26 |
MX2016001023A (es) | 2016-04-19 |
US20190175543A1 (en) | 2019-06-13 |
CN108938583B (zh) | 2021-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201905586T4 (tr) | Amorf dapagli̇flozi̇n i̇çeren formülasyonlar | |
PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
PH12014501738A1 (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
PH12015501648A1 (en) | 2-aminopyrimidine derivatives for the treatment of viral infections | |
MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
PH12015500983A1 (en) | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
GB201209613D0 (en) | New compounds | |
PH12015500724B1 (en) | 1, 2, 4-triazine derivatives for the treatment of viral infections | |
PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
HN2010002518A (es) | Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
MX2014009244A (es) | Una composicion y uso de la misma en el tratamiento de ragades anales. | |
MX364528B (es) | Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas. | |
MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
MX360885B (es) | Nuevas composiciones antifungicas. | |
UA103450C2 (ru) | Фолат-конъюгированный ферроцен как биологически активное соединение медицинского назначения |